[ad_1]
As it has occurred in other countries in recent months, the Bolivian Ministry of Health has decided to suspend the sale of all drugs containing valsartan of Chinese origin, because they are suspected of containing a carcinogenic element.
The decision was announced Tuesday by the State Agency for Medicines and Health Technologies (Agemed), which also launched a health alert for this reason, reports the newspaper El Deber, Santa Cruz
The institution explains that she made the decision that the European Medicines Agency (EMA) is examining drugs containing this active substance.
The active substance of this product, supplied by Zhejiang Huahai Pharmaceuticals, contains the impurity Nnitrosodimethylamine (NDMA), which has been classified as "probably carcinogenic" by the International Agency for Research on Cancer (IARC) .
This item is part of the treatments for essential hypertension and heart failure.
The measure adopted by the Ministry of Health will continue until the conclusion of the investigation conducted by the EMA and the official communication of the Ministry of Health. World Health Organization.
"While research is underway and until obtaining an official statement from the World Health Organization (WHO), the National Agency for drugs and health technologies has determined the marketing suspension of drugs containing valsartan of Chinese origin, "says part of the statement issued by Agemed. (19/07/2018)
Source link
